Full text loading...
Abstract
Indolcarboxamides are a promising series of anti-tubercular agents, which target Mycobacterium tuberculosis MmpL3, the exporter of trehalose monomycolate, a key cell-wall component. We determined the kill kinetics of the lead indolcarboxamide NITD-349 and determined that while kill was rapid against low-density cultures, bactericidal activity was inoculum-dependent. A combination of NITD-349 with isoniazid (which inhibits mycolate synthesis) had an increased kill rate; this combination prevented the appearance of resistant mutants, even at higher inocula.
- Received:
- Accepted:
- Published Online:
Keyword(s):
anti-tubercular
,
bactericidal activity
,
cell-wall inhibitor
and
tuberculosis drug discovery
Funding
-
Bill and Melinda Gates Foundation
(Award INV-005585)
- Principle Award Recipient: TanyaParish
-
Bill and Melinda Gates Foundation
(Award OPP1024038)
- Principle Award Recipient: TanyaParish
-
National Institutes of Health
(Award R01AI129360)
- Principle Award Recipient: TanyaParish
© 2023 The Authors